Boston Scientific Cuts Organic Growth Forecast, Stock Falls to 52‑Week Low

Executives pointed to weaker WATCHMAN standalone procedures and softness in electrophysiology and urology, pushing shares down as management leans on buybacks and positive trial data to support value.

Overview

Management reduced full-year organic growth guidance to 6.5%–8% and set second-quarter organic growth at 5%–7% during remarks at Bernstein’s Strategic Decisions Conference.
Shares tumbled about 10% intraday and hit an intraday low of $50.75, a new 52‑week low, as investors repriced the stock on the weaker outlook.
Leadership blamed the downgrade on falling standalone WATCHMAN procedures that began in February plus softer demand in electrophysiology and urology, and cited hospital capacity limits, reimbursement shifts, tariff pressure, and competitive share loss in EP as added headwinds.
Most analysts still carry Buy or Overweight ratings but several trimmed targets and the range of price forecasts widened to roughly $60–$90, reflecting disagreement over near‑term risk and long‑term value.
Company offsets include a $5 billion repurchase program with about $3 billion left and a recent $2 billion accelerated buyback, plus positive pivotal FRACTURE trial results for the SEISMIQ 4CE device, which together may help stabilize shares if procedure volumes recover.